Development, pharmacology, role of DT-diaphorase and prospects of the indoloquinone EO9

1. 1. The indoloquinone EO9 (3-hydroxymethyl-5-aziridinyl-l-methyl-2.(1H.indole-4,7-dione)-propenol; E85/053; NSC 382,459) is a synthetic bioreductive alkylating agent that is structurally related to mitomycin C (MMC). 2. 2. EO9 does, however, show a different mechanism of action and a broader antit...

Full description

Saved in:
Bibliographic Details
Published in:General Pharmacology 1996-04, Vol.27 (3), p.421-429
Main Authors: Smitskamp-Wilms, E., Hendriks, H.R., Peters, G.J.
Format: Article
Language:English
Subjects:
Animals
Antineoplastic agents
Antineoplastic Agents - pharmacology
Aziridines - pharmacology
Biological and medical sciences
Chemotherapy
Enzyme Activation - drug effects
Humans
Indolequinones
Indoles - pharmacology
Medical sciences
NAD(P)H Dehydrogenase (Quinone) - metabolism
Oxidation-Reduction
Pharmacology. Drug treatments
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:1. 1. The indoloquinone EO9 (3-hydroxymethyl-5-aziridinyl-l-methyl-2.(1H.indole-4,7-dione)-propenol; E85/053; NSC 382,459) is a synthetic bioreductive alkylating agent that is structurally related to mitomycin C (MMC). 2. 2. EO9 does, however, show a different mechanism of action and a broader antitumour profile than MMC. It is also a more potent cytotoxic agent in vitro than MMC, probably because of its impressive efficient activation by reductive enzymes, particularly DT-Diaphorase. This enzyme is elevated in several tumours compared to normal tissues. 3. 3. The preferential cytotoxicity of EO9 under hypoxic conditions makes it an interesting compound to combine with radiation. 4. 4. In preclinical and the Phase I clinical studies, no myelosuppression was observed but reversible proteinuria was dose-limiting. Phase II clinical studies were started in the summer of 1994.
ISSN:0306-3623
1879-0011
DOI:10.1016/0306-3623(95)00118-2